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patients were biologic-experienced, and 52 (34%) were biologic-naïve before initi-
ating golimumab. A higher percentage of female patients were in the bio-experi-
enced category (70% vs. 55%). Osteoarthritis (27%), hypertension (24%), dyslipide-
mia (17%), and depressive disorders (14%) were the most common comorbidities
prior to the start of golimumab. A higher rate of depressive disorder was observed
in the biologic-experienced group. Baseline mean C-reactive protein test values
were also higher in the biologic-experienced group (3.69 vs. 0.97). Biologic-experi-
enced patients on golimumabwere switchedmostly from adalimumab (n42) and
etanercept (n25). CONCLUSIONS: In this longitudinal EMR, patients receiving
golimumab were more likely to have prior biologic experience. Biologic-experi-
enced patients appeared to have higher C-reactive protein test values and greater
rates of depressive disorders than their biologic-naïve counterparts.
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OBJECTIVES: Golimumab (GLM) is a monthly self-injected anti-tumor necrosis fac-
tor alpha therapy providing once-monthly dosing for patients with rheumatoid
arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA). This study
assesses the baseline characteristics and utilization patterns of patients who re-
ceived GLM. METHODS: We performed a retrospective database analysis of The
MarketScan® Research Database from Thomson Reuters. This database contains
individual-level, de-identified, healthcare claims information from employers,
health plans, hospitals, Medicare, and Medicaid. A total of 29,774 patients in this
database had a diagnosis of either RA, PsA or AS and at least one biologic on record
and met the following inclusion criteria: 18 years of age at the time of the first
diagnosis. From this sample, a total of 174 patients had at least one prescription
record for GLM. RESULTS: A total of 174 patients receiving GLM were identified as
meeting all the inclusion criteria; with 128 (RA), 30 (PSA), and 16 (AS). Themean age
was 48 years and 75% of the sample was female. A total of 155 (89%) patients were
bio-experienced and 19 (11%)were bio-naïve before initiating golimumab. A total of
111 patients received at least two GLMdoses. Of the patients with two ormore GLM
doses, the median and mean SD dosing interval was 29.5 days and 33.65  15.56
days. When looking at biologic naïve patients the median and mean SD dosing
interval was 30 days and 35.37  17.63 days versus biologic experienced patients
with a dosing interval of 29 days and 33.15  15.00 days. CONCLUSIONS: In the
MarketScan database, the majority of patients with a prescription for GLM was
female and had prior biologic experience. GLM median and mean doses were 29.5
and 33.37 days respectively. Previous biologics experience did not significantly
change the GLM dosing patterns.
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OBJECTIVES: Golimumab, a newer anti-tumor necrosis factor agent used in patients
with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, has recom-
mendeddosing of 50mgoncemonthly. The objective of this studywas to describe the
biologic experience and dosing for patients using golimumab in the managed care
setting. METHODS: The IMS LifeLink™ Health Plan database (100 managed care
plans) was utilized to identify patients aged 18 years at index and having an index
golimumab pharmacy claim started between 4/24/2009 (product approval) and 10/31/
2009. Patients were required to have 24 months pre- and  2 months post-index
continuous enrollment with 1 RA, PsA, or AS ICD-9 diagnosis code. Biologic experi-
encewas assessed for the pre-index period. Dosingwas assessed through end of data
or loss of enrollment. RESULTS: A total of 282 patients receiving golimumab were
identified; 72%were female;meanagewas52years.Themajority (73%) of patientshad
pre-index biologic experience. Among the biologic-experienced, 60% received 1
unique biologic, 33% received 2 unique biologics, and 7% received 3 unique biologics
before golimumab. Golimumabpatients had experiencewith various combinations of
abatacept, adalimumab, certolizumab, etanercept, and infliximab.Adalimumabalone
and etanercept aloneweremost frequently used prior to golimumab. The golimumab
dose at each of the first six prescription fills was 50 mg for over 97% of patients. The
mean (median) days between fills spanned 29-33 (29-30) days. CONCLUSIONS: The
majority ofpatients receivinggolimumabwerebiologic-experienced.Observeddosing
was consistent with prescribing recommendations. Consistency in dosing was ob-
served over the first six prescriptions. Despite the history of biologic use, golimumab
patientsdidnothaveanapparent increaseddose requirementupon initiation. Further
research is necessary to confirm these findings in a larger sample size over a longer
duration of follow-up.
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OBJECTIVES: To understand the reasons for initiating an intravenous (IV) biologic
therapy among prior subcutaneous injection (SQ) users, and patient satisfaction
before and after switching.METHODS: Semi-structured telephone interviewswere
conducted with 405 immunology patients currently receiving IV biologic therapy.
Patients rated their level of satisfaction with current or prior medication on a
7-point Likert scale (7Very satisfied; 1not at all satisfied) and reported reasons
for switching from SQ therapy. RESULTS: More than a third (37%) of surveyed IV
biologic patients previously used SQ administration. Of these patients, overall
mean satisfaction with SQ was 3.8, with 32% rating the SQ experience as a 1 or 2.
Current IV satisfaction ratings among prior SQ users was 6.2 (vs. 6.1 for all patients
surveyed). Of prior SQ users, 26% did not self-administer their injections, most
frequently due to: dislike of needles; lack of confidence in own ability to administer
the injection correctly; and/or physical inability to handle the syringe. Of thosewho
did not self-administer SQ, 39% went to a physician’s office for administration.
Primary reasons for switching from SQ to IV administration included lack of effi-
cacy (81%), side effects (21%), cost (10%) and dislike of self injections (9%).
CONCLUSIONS: In this analysis, current IV biologic users appear highly satisfied
with this medication. Dissatisfied SQ users that did not self-administer may offset
potential “convenience” advantages of a SQ. They also switched to IV mostly for
loss of efficacy and appear to be satisfied with an IV. Given the potential for patient
preference differences, there appears a need for expanded treatment choices. In-
volving the patient in shared decision making and providing access to both IV and
SQ modes of administration may be important to optimizing patient satisfaction.
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OBJECTIVES: To evaluate treatment patterns when different definitions of discontin-
uation are used. Anti-tumor necrosis factor therapies including adalimumab (ADA),
etanercept (ETA) and infliximab (IFX) are used to treat rheumatoid arthritis (RA). Ex-
amining discontinuation rates can help understanding of real-world treatment pat-
terns. Different definitions of discontinuation rates have been reported elsewhere.
METHODS: Data between 01/2005-06/2006 were extracted from the i3Innovus data-
base. Inclusion criteria were aged18,1 claim for RA, and no evidence of pre-index
biologic use in the sixmonths prior. Patients were followed for 24months. Discontin-
uationwasdefinedasagap in therapy60or365days following the lastdayssupply.
RESULTS: Total of 1,780 patientswere analyzed: ADA 601 (33.8%); ETA 785 (44.1%);
IFX394 (22.1%). If discontinuationwas defined as a gap in therapy of60 days, 57.2%
of patients treated with ADA discontinued, 57.5% of patients treated with ETA and
37.6% of IFX patients discontinued. If discontinuationwas defined as a gap in therapy
of 365 days, 22.5% of ADA patients discontinued, 17.3% of ETA patients and 18% of
IFX patients discontinued. Of those defined as ‘discontinuers’ after a gap of therapy of
60 days, 49.7 % of ADA patients, 62.1% of ETA patients and 12.8% of IFX patients
restarted their index therapy on average 146.8, 146.5, and 302.4 days from the time of
defined ‘discontinuation’. Significantly fewer IFX patients restarted their index ther-
apy (P0.0001) and the time from defined discontinuation to restart was longer
(p0.0001). CONCLUSIONS: This analysis demonstrates that different discontinua-
tion rates are observed when different definitions of discontinuation are employed.
This may impact the understanding of real-world prescribing patterns. The data also
suggests that patients treated with ADA and ETA experience lengthy gaps in therapy.
Future research is needed to examine gaps in therapy on clinical andhealth economic
outcomes.
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OBJECTIVES: Prior etanercept drug utilization studies have reported, that among
patients with a gap in observed refill time exceeding the recommended refill time,
31%-44%of patients experienced gaps greater than 2weeks.Mean gaps (assessed at
each individual refill period) ranged from 19 to 37 days. Limited comparative data
exist for infliximab. The objective of this modeling analysis was to assess the
impact on drug levels from gaps in prescription refill behavior that may result in
under-dosing. METHODS: Steady state concentration models for etanercept and
infliximab were developed to simulate the effect of missed dosing (i.e., gap in
etanercept prescription refill or infliximab administration interval). Results were
expressed as a percent of steady state trough levels (SSTL) in g/mL, and were
presented to simulate gaps that varied from 1-5 weeks. Population pharmacoki-
netic models for etanercept and infliximab were used to simulate out steady state
concentration profiles. The parameters used in these models were extracted from
recent publications. RESULTS: After a refill or administration gap of one week,
etanercept and infliximab concentrations were at 13% and 73% of SSTL respec-
tively. At two weeks, SSTL were 4% and 55% respectively. Etanercept levels were
effectively non-existent after three weeks, whereas infliximab was at 40% of SSTL.
Clinical implications were not simulated. CONCLUSIONS: SSTL of etanercept de-
clines rapidly with gaps in refills and disappears with gaps as short as three weeks.
Infliximab demonstrates a muchmore gradual decline. Poor patient refill behavior
may have consequences that go beyond declining drug levels, and patient adher-
ence risk should be an integral part of any discussion during shared treatment
decision making.
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OBJECTIVES: Provider continuity is defined as seeing the samehealth care provider
over time. Previous studies indicated that high provider continuity improves
health care outcomes and the efficiency of health care delivery. The impact of
provider continuity in sickle cell disease (SCD) care, however, is unknown. This
study examined the association between provider continuity and the risk of SCD-
related hospitalization and re-hospitalization within 30 days of discharge.
METHODS: A retrospective cohort study was conducted using Florida Medicaid
claims data from 2001-2005. Patients with claims containing SCD-related ICD-9
codes (282.41-282.42, 282.6- 282.64, 282.68-282.69) were selected. To be eligible,
individuals had to be aged65 years, continuously enrolled in Medicaid, and have
made2 ambulatory visits.Modifiedmodified continuity index (MMCI) scoreswere
calculated to quantify provider continuity. Cox proportional hazard modeling was
used to examine the relationship between MMCI and hospitalization and 30-day
re-hospitalization controlling for basic demographics, prior utilization, SCD treat-
ments and complications. RESULTS: A total of 2422 patients with mean age of 10.2
(SD11.9) and 47.2% male were included. Average MMCI score was 0.60 (SD0.28),
53.47% had 1 SCD-related hospitalization; of those, 18.8% were re-hospitalized
within 30 days. After controlling for patient-level factors, patients with higher
provider continuity were less likely to be hospitalized (HR0.53, 95% CI: 0.44-0.65),
but MMCI was not significantly associated with 30-day risk of re-hospitalization
(HR0.89, 95% CI0.55-1.43). CONCLUSIONS:Higher provider continuity was asso-
ciated with a lower risk of SCD-related hospitalization in the Florida Medicaid SCD
population, but did not affect the rate of 30-day re-hospitalization. Policies that
improve andmaintain continuity between SCD patients and a single provider may
lead to lower hospitalization rates and possibly lower health care costs.
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OBJECTIVES: Thrombocytopenia, or low blood platelet count, is associated with
disease progression and treatment for several chronic conditions, including liver
disease, cancer, and HIV. Yet, little information describing the impact of thrombo-
cytopenia on patients is available. This study compared indicators of health and
functional status among individuals with and without thrombocytopenia.
METHODS: 1999-2008 National Health and Nutrition Examination Survey
(NHANES) data were used to identify individuals aged 20 years with normal and
low platelets, using a threshold of 150x109/L. Indicators of health and/or functional
status included self-reported general health [1-5 scale, 1excellent], number of
health care visits and overnight hospital stays, days physical health was not good,
inactive days due to physical health, and work limitations. Weighted means and
frequencies were summarized and compared using paired t-tests and chi-squared
tests, respectively. RESULTS: 22,959/25,772 participants aged 20 years had infor-
mation on platelets. Of these, 526 (1.9%) had low platelets at the time of examina-
tion. Individuals with thrombocytopenia were older (51.7 vs 37.2 years) and more
likely to be male (67.7% vs 48.6%), infected with hepatitis C (7.4% vs 1.4%), and ever
diagnosed with cancer (14.2% vs 8.0%) or a liver condition (12.3% vs 3.1%), p.05 for
all. Fewer participantswith thrombocytopenia reported excellent health compared
to those with normal platelets (12.5% vs 16.5%, p.0001). Participants with throm-
bocytopenia reported more health care provider visits (2.35 vs 2.02, p.0001) and
were more likely to report an overnight hospital stay (0.19% vs 0.11%, p.001).
Participants with thrombocytopenia hadmore inactive days due to physical health
and were more likely to face work limitations (p.01 for all). CONCLUSIONS:
Thrombocytopenia is associated with limitations on functional status and in-
creased health care utilization, some of which may be related to patients’ under-
lying health conditions. Further study is needed to determine the incremental
impact of thrombocytopenia.
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OBJECTIVES: Minimal health-related quality of life (HRQOL) data have been pub-
lished on myelodysplastic syndromes (MDS) patients in the United States. This
analysis characterized HRQOL by age group of MDS pts treated with Vidaza® in the
AVIDA® registry.METHODS: Data were collected from AVIDA, a Vidaza treatment
registry, initiated in US community clinics. Clinicians provided patient demo-
graphic, treatment pattern, and clinical outcome data. Patients reported HRQOL
(EORTC-QLQ-C30) within 2 months of treatment initiation. Mean (Standard Devia-
tion [SD]) scores on global health status (GHS), 5 functional scales and 9 symptom/
other scales were analyzed by age: 65, 65-74, 75 years. Statistical significance
was ascertained by ANOVA using SAS 9.1. RESULTS: Data were reported from 99
clinics on 427 pts:65 (n68), 65-74 (n127), and75 (n232) years.Mean (SD) GHS
was 54.8 (1.2) overall, and similar among age groups: 53.9 (2.9), 54.7 (2.1), and 55.2
(1.6), p0.9263. Similarly, physical, role, and social functioning were comparable.
Emotional and cognitive functioning, however, were worse among those 65 ver-
sus the older groups: 66.2 (3.5), 78.6 (1.8), 79.5 (1.5), p0.0001 for emotional, and 72.4
(3.5), 82.7 (1.7), 80.3 (1.4), p0.0067 for cognitive. The 65 cohort reported signifi-
cantly worse scores on 4 of 9 symptom/other scores: financial difficulties (34.8 (4.5),
15.3 (2.4), 13.0 (1.7), p0.0001); insomnia (39.7 (4.0), 27.5 (2.7), 27.3 (2.2), p0.0141);
appetite loss (29.9 (3.8), 18.4 (2.5), 25.3 (2.1), p0263); and fatigue 53.9 (3.1), 44.3 (2.3),
48.5 (1.8), p0.0452). CONCLUSIONS: AVIDA registry findings indicate baseline
HRQOL among MDS patients in real world settings differs by age in certain do-
mains. Findings suggest HRQOL is similar or better in elderly MDS patients than
younger patients. These differences in emotional and cognitive functioning, fa-
tigue, insomnia, appetite loss, and financial difficulties require consideration by
clinicians in managing MDS patients.
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OBJECTIVES: Chronic pain is a major public health concern in the US. Established
guidelines are available formanagement of non-malignant chronic pain, including
opioid use. However, discrepancies in opioid prescribing patterns due to physician
misconceptions remain concerning. Therefore, this study evaluated pain medica-
tion use and investigated determinants of opioid analgesic prescribing in the US
outpatient settings for common non-malignant chronic pain indications.
METHODS: This cross-sectional study analyzed the National Ambulatory Medical
Care Survey(NAMCS) data from 2002-2007 on patients 18 years and older with
non-malignant chronic pain diagnosis based on ICD-9-CM codes identified as rea-
son for visits. Painmedications prescribedwere retrieved usingNAMCSdrug codes.
Multivariate logistic models examined determinants of opioid prescribing among
chronic pain patients. RESULTS: Approximately 69 million weighted outpatient
visits were reported for non-malignant chronic pain between 2000-2007 in the US.
The mean age for patients was 53 (range 18-100) and the majority were
women(63%). Neuropathic pain was reported for 2.39% visits while 16.24% had an
inflammatory pain diagnosis. Non-medication treatment was prescribed during
26% of these visits. While most(95%) visits reported prescribing NSAIDs, 29% re-
ported receiving prescriptions for more than five medications. Primary care physi-
cians (PCPs) were 1.74 times more likely to prescribe opioids [OR(odds ratio):1.74,
CI:1.42-2.14] than other specialty physicians. Patients receiving more than five
medications were 2.80 times more likely to receive opioids (OR:2.80,CI:2.28-3.44)
than thosewith less thanfivemedications. Patients from the southern region of the
US were 1.43 times more likely to receive opioids (OR:1.43,CI:1.06-1.94) than pa-
tients from the northeast region. CONCLUSIONS: According to our study, visits
with PCPs, more than five prescriptions, established patients, and physician visits
in the southern region of the US were some of the determinants of opioid prescrib-
ing. Increased awareness of opioid prescription guidelines for pain management
may eliminate prescription discrepancies and improve patient care.
PSY74
TREATMENT CHOICE FOR PAIN MANAGEMENT IN NURSING HOME HOSPICE/
PALLIATIVE CARE RESIDENTS IN THE UNITED STATES
Agrawal R, Mhatre SK, Sansgiry S
University of Houston, Houston, TX, USA
OBJECTIVES: This study determined factors associated with treatment choice for
pain management in US nursing home hospice/palliative care residents.
METHODS: This is a cross sectional study of data from the resident file of the 2004
National Nursing Home Survey (NNHS). Residents assigned to a bed in a hospice
specialty unit or receiving services from a special program for hospice/palliative
care in 1174 systematically selected nursing homes and having pain in 7 days
before the surveywere included. Treatment choices included standing order (SO) of
analgesics, as-needed orders (PRN) of analgesics and non-pharmacological treat-
ment (NPT). Factors evaluated were gender, marital status, age, ethnicity, eating
limitation, toilet limitation, urinary incontinence and bowel incontinence.
Weighted descriptive analysis, bivariate analysis using chi-square tests and mul-
tivariate analysis using logistic regression were conducted using SAS version 9.2 to
determine factors associated with pain management. RESULTS: Overall 22.6%
(338,029/1,492,207,weighted) patients met the study inclusion criteria. Mean[SD]
age was 79.1[13.3] years, 74.7% were females and 89.8% were white. 78.6%, 49.8%,
and 29.3% received PRN, SO, and NPT, respectively. Logistic regression showed
higher likeliness to receive SO for patients of age at or above 65 years (OR1.51 95%
CI1.184-1.948 P0.001), patients with bowel incontinence (OR1.21 95%
CI1.020-1.437 P0.028) and Medicaid patients (OR1.5 95% CI1.258-1.799
P0.0001). Likeliness to receive PRN was lower for patients of age at or above 65
years (OR0.60 95% CI0.428-0.841 P0.0031), patients with bowel incontinence
(OR0.67 95%CI0.533-0.859 P0.0014), Medicaid patients (OR0.65 95%CI0.525-
0.806 P0.0001) and Hispanics (OR0.327 95% CI0.204-0.527 P0.001). Likeliness
to receive NPT was higher for patients with toileting limitation (OR2.905 95%
CI1.135-7.434 P0.026) and lower for patients with urinary incontinen-
ce(OR0.022 95% CI0.003-0.172 P0.0003). CONCLUSIONS: Factors affecting
treatment choice were age, bowel and urinary incontinence, toileting limitations,
ethnicity and insurance type and can be targeted in future studies aiming at man-
agement of pain in nursing homes.
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